Novo Nordisk completes acquisition of Akero Therapeutics
Akero became a wholly owned subsidiary of Novo Nordisk
Akero became a wholly owned subsidiary of Novo Nordisk
Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
Abbott is eyeing to become a global powerhouse in early cancer detection and precision oncology
The proposed transaction will be effected as a share swap
The issue comprises a fresh issue of Rs. 95 crore and targeting a total raise of around Rs. 895 crore
Subscribe To Our Newsletter & Stay Updated